Literature DB >> 22286861

Androgen deprivation therapy-associated vasomotor symptoms.

Jason M Jones1, Manish Kohli, Charles L Loprinzi.   

Abstract

Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of locally advanced and metastatic prostate cancer. While efficacious, ADT is associated with multiple side effects, including decreased libido, erectile dysfunction, diabetes, loss of muscle tone and altered body composition, osteoporosis, lipid changes, memory loss, gynecomastia and hot flashes. The breadth of literature for the treatment of hot flashes is much smaller in men than that in women. While hormonal therapy of hot flashes has been shown to be effective, multiple non-hormonal medications and treatment methods have also been developed. This article reviews current options for the treatment of hot flashes in patients taking ADT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286861      PMCID: PMC3338189          DOI: 10.1038/aja.2011.101

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  64 in total

1.  Reimbursement policy and androgen-deprivation therapy for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Scott M Gilbert
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Hot flushes: mostly sex neutral?

Authors:  Charles L Loprinzi; Sherry L Wolf
Journal:  Lancet Oncol       Date:  2009-12-04       Impact factor: 41.316

3.  Menopausal flushing: double-blind trial of a non-hormonal medication.

Authors:  J R Clayden; J W Bell; P Pollard
Journal:  Br Med J       Date:  1974-03-09

4.  Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer.

Authors:  M Naoe; Y Ogawa; T Shichijo; K Fuji; T Fukagai; H Yoshida
Journal:  Prostate Cancer Prostatic Dis       Date:  2006-06-20       Impact factor: 5.554

5.  Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study.

Authors:  M Hammar; J Frisk; O Grimås; M Höök; A C Spetz; Y Wyon
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

6.  Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study.

Authors:  G Bertelli; M Venturini; L Del Mastro; M Bergaglio; P Sismondi; N Biglia; S Venturini; G Porcile; P Pronzato; M Costantini; R Rosso
Journal:  Ann Oncol       Date:  2002-06       Impact factor: 32.976

7.  Transdermal clonidine for ameliorating post-orchiectomy hot flashes.

Authors:  C L Loprinzi; R M Goldberg; J R O'Fallon; S K Quella; A W Miser; L A Mynderse; L D Brown; L K Tschetter; M B Wilwerding; M Dose
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

8.  Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study.

Authors:  Eugene G Lipov; Jaydeep R Joshi; Sarah Sanders; Kris Wilcox; Sergei Lipov; Hui Xie; Robert Maganini; Konstantin Slavin
Journal:  Lancet Oncol       Date:  2008-05-15       Impact factor: 41.316

9.  A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.

Authors:  David F Archer; Larry Seidman; Ginger D Constantine; James H Pickar; Sophie Olivier
Journal:  Am J Obstet Gynecol       Date:  2008-12-25       Impact factor: 8.661

Review 10.  Andropause: symptom management for prostate cancer patients treated with hormonal ablation.

Authors:  Carrie A Thompson; Tait D Shanafelt; Charles L Loprinzi
Journal:  Oncologist       Date:  2003
View more
  5 in total

1.  Time to raise awareness regarding complications of androgen deprivation therapy.

Authors:  Shehzad Basaria
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 2.  Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.

Authors:  Hamed Ahmadi; Siamak Daneshmand
Journal:  Patient Relat Outcome Meas       Date:  2014-07-05

Review 3.  Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management.

Authors:  Anton M F Kalsbeek; Eva K F Chan; Niall M Corcoran; Christopher M Hovens; Vanessa M Hayes
Journal:  Oncotarget       Date:  2017-08-04

4.  Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.

Authors:  Petros Sountoulides; Thomas Rountos
Journal:  ISRN Urol       Date:  2013-07-25

5.  Effects of a six-month supervised physical exercise program on physical and cardio-metabolic profile and quality of life in patients with prostate cancer on androgen deprivation therapy: a pilot and feasibility study.

Authors:  Natalia S Zabegalina; Michaël M E L Henderickx; Veerle Lamotte; Bart Segers; Gaetane Stassijns; Stefan De Wachter; Lucien Hoekx
Journal:  Cent European J Urol       Date:  2018-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.